中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 3
Mar.  2023
Turn off MathJax
Article Contents

Influence of the interaction between tumor microenvironment and liver cancer stem cells on the development and progression of hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2023.03.032
Research funding:

National Natural Science Foundation of China (82274260)

More Information
  • Corresponding author: ZHU Ying, zhuyingsh52@126.com (ORCID: 0000-0002-0624-7974)
  • Received Date: 2022-07-11
  • Accepted Date: 2022-09-30
  • Published Date: 2023-03-20
  • In recent years, liver cancer stem cells (LCSC) have been considered one of the main causes of treatment failure and recurrence of hepatocellular carcinoma (HCC). Many studies have shown that LCSC are a small fraction of cells with the abilities of self-renewal, differentiation, and tumorigenesis in HCC tumor, which can initiate the onset of HCC and affect its proliferation, invasion, metastasis, recurrence, and drug resistance. Therapies based on tumor microenvironment (TME) have been developed recently, and a number of studies have found that targeting the relevant elements of TME has a higher therapeutic value than targeting tumor cells themselves. TME is the microenvironment for the growth of LCSC and HCC cells, and it interacts with LCSC and has a synergistic effect, thereby playing a positive role in the development and progression of HCC. This article introduces how various cellular components and non-cellular components in TME interact with LCSC to regulate the development and progression of the HCC. In addition, this article also describes the molecular targets, therapies, and drugs associated with the main components of TME and LCSCs, in order to seek safer and more effective targeted therapies for HCC.

     

  • loading
  • [1]
    RUTHERFORD MJ, ARNOLD M, BARDOT A, et al. Comparison of liver cancer incidence and survival by subtypes across seven high-income countries[J]. Int J Cancer, 2021, 149(12): 2020-2031. DOI: 10.1002/ijc.33767.
    [2]
    LV D, CHEN L, DU L, et al. Emerging regulatory mechanisms involved in liver cancer stem cell properties in hepatocellular carcinoma[J]. Front Cell Dev Biol, 2021, 9: 691410. DOI: 10.3389/fcell.2021.691410.
    [3]
    ZHENG X, YU C, XU M. Linking tumor microenvironment to plasticity of cancer stem cells: mechanisms and application in cancer therapy[J]. Front Oncol, 2021, 11: 678333. DOI: 10.3389/fonc.2021.678333.
    [4]
    TONTI OR, LARSON H, LIPP SN, et al. Tissue-specific parameters for the design of ECM-mimetic biomaterials[J]. Acta Biomater, 2021, 132: 83-102. DOI: 10.1016/j.actbio.2021.04.017.
    [5]
    YE J, WU D, WU P, et al. The cancer stem cell niche: cross talk between cancer stem cells and their microenvironment[J]. Tumour Biol, 2014, 35(5): 3945-3951. DOI: 10.1007/s13277-013-1561-x.
    [6]
    LAM KH, MA S. Noncellular components in the liver cancer stem cell niche: Biology and potential clinical implications[J]. Hepatology, 2022. DOI: 10.1002/hep.32629. [Online ahead of print]
    [7]
    KAPLAN RN, RIBA RD, ZACHAROULIS S, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche[J]. Nature, 2005, 438(7069): 820-827. DOI: 10.1038/nature04186.
    [8]
    ZHENG N, ZHANG S, WU W, et al. Regulatory mechanisms and therapeutic targeting of vasculogenic mimicry in hepatocellular carcinoma[J]. Pharmacol Res, 2021, 166: 105507. DOI: 10.1016/j.phrs.2021.105507.
    [9]
    GUO Y, XIAO Z, YANG L, et al. Hypoxia-inducible factors in hepatocellular carcinoma (Review)[J]. Oncol Rep, 2020, 43(1): 3-15. DOI: 10.3892/or.2019.7397.
    [10]
    BORT A, SÁNCHEZ BG, MATEOS-GÓMEZ PA, et al. Targeting AMP-activated kinase impacts hepatocellular cancer stem cells induced by long-term treatment with sorafenib[J]. Mol Oncol, 2019, 13(5): 1311-1331. DOI: 10.1002/1878-0261.12488.
    [11]
    JING L, RUAN Z, SUN H, et al. Epithelial-mesenchymal transition induced cancer-stem-cell-like characteristics in hepatocellular carcinoma[J]. J Cell Physiol, 2019, 234(10): 18448-18458. DOI: 10.1002/jcp.28480.
    [12]
    CHENG Z, LI X, DING J. Characteristics of liver cancer stem cells and clinical correlations[J]. Cancer Lett, 2016, 379(2): 230-238. DOI: 10.1016/j.canlet.2015.07.041.
    [13]
    PATIL SM, SAWANT SS, KUNDA NK. Exosomes as drug delivery systems: A brief overview and progress update[J]. Eur J Pharm Biopharm, 2020, 154: 259-269. DOI: 10.1016/j.ejpb.2020.07.026.
    [14]
    CHEN H, NIO K, YAMASHITA T, et al. BMP9-ID1 signaling promotes EpCAM-positive cancer stem cell properties in hepatocellular carcinoma[J]. Mol Oncol, 2021, 15(8): 2203-2218. DOI: 10.1002/1878-0261.12963.
    [15]
    MODI SJ, KULKARNI VM. Discovery of VEGFR-2 inhibitors exerting significant anticancer activity against CD44+ and CD133+ cancer stem cells (CSCs): Reversal of TGFβ induced epithelial-mesenchymal transition (EMT) in hepatocellular carcinoma[J]. Eur J Med Chem, 2020, 207: 112851. DOI: 10.1016/j.ejmech.2020.112851.
    [16]
    FUJITA J, SAKURAI T. The oncoprotein gankyrin/PSMD10 as a target of cancer therapy[J]. Adv Exp Med Biol, 2019, 1164: 63-71. DOI: 10.1007/978-3-030-22254-3_5.
    [17]
    JAFERIAN S, SOLEYMANINEJAD M, NEGAHDARI B, et al. Stem cell, biomaterials and growth factors therapy for hepatocellular carcinoma[J]. Biomed Pharmacother, 2017, 88: 1046-1053. DOI: 10.1016/j.biopha.2017.01.154.
    [18]
    YAMASHITA T, HONDA M, NIO K, et al. Oncostatin m renders epithelial cell adhesion molecule-positive liver cancer stem cells sensitive to 5-Fluorouracil by inducing hepatocytic differentiation[J]. Cancer Res, 2010, 70(11): 4687-4697. DOI: 10.1158/0008-5472.CAN-09-4210.
    [19]
    ZHENG W, YAO M, WU M, et al. Secretory clusterin promotes hepatocellular carcinoma progression by facilitating cancer stem cell properties via AKT/GSK-3β/β-catenin axis[J]. J Transl Med, 2020, 18(1): 81. DOI: 10.1186/s12967-020-02262-7.
    [20]
    CHEN L, CHENG MM, LI YP, et al. 4, 4'-Bond secalonic acid D targets SP cells and inhibits metastasis in hepatocellular carcinoma[J]. Mol Med Rep, 2020, 21(6): 2624-2632. DOI: 10.3892/mmr.2020.11055.
    [21]
    EGUCHI T, SHETA M, FUJⅡ M, et al. Cancer extracellular vesicles, tumoroid models, and tumor microenvironment[J]. Semin Cancer Biol, 2022, 86(Pt 1): 112-126. DOI: 10.1016/j.semcancer.2022.01.003.
    [22]
    ZHANG G, HUANG X, XIU H, et al. Extracellular vesicles: Natural liver-accumulating drug delivery vehicles for the treatment of liver diseases[J]. J Extracell Vesicles, 2020, 10(2): e12030. DOI: 10.1002/jev2.12030.
    [23]
    BORRELLI DA, YANKSON K, SHUKLA N, et al. Extracellular vesicle therapeutics for liver disease[J]. J Control Release, 2018, 273: 86-98. DOI: 10.1016/j.jconrel.2018.01.022.
    [24]
    AFIFY SM, HASSAN G, YAN T, et al. Cancer stem cell initiation by tumor-derived extracellular vesicles[J]. Methods Mol Biol, 2022, 2549: 399-407. DOI: 10.1007/7651_2021_371.
    [25]
    WANG H, LU Z, ZHAO X. Tumorigenesis, diagnosis, and therapeutic potential of exosomes in liver cancer[J]. J Hematol Oncol, 2019, 12(1): 133. DOI: 10.1186/s13045-019-0806-6.
    [26]
    JI J, YAMASHITA T, BUDHU A, et al. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells[J]. Hepatology, 2009, 50(2): 472-480. DOI: 10.1002/hep.22989.
    [27]
    YUAN SX, WANG J, YANG F, et al. Long noncoding RNA DANCR increases stemness features of hepatocellular carcinoma by derepression of CTNNB1[J]. Hepatology, 2016, 63(2): 499-511. DOI: 10.1002/hep.27893.
    [28]
    LI N. The study on fuction and molecular mechanism of p28~(Gank)、IRAKI in macrophage and HCC[D]. Shanghai: Shanghai Jiao Tong University, 2015. DOI: 10.27307/d.cnki.gsjtu.2015.000503.

    李宁. p28~(Gank)、IRAK1在巨噬细胞以及肝癌中的功能及机制研究[D]. 上海: 上海交通大学, 2015. DOI: 10.27307/d.cnki.gsjtu.2015.000503.
    [29]
    ZHAO Z, BAI S, WANG R, et al. Cancer-associated fibroblasts endow stem-like qualities to liver cancer cells by modulating autophagy[J]. Cancer Manag Res, 2019, 11: 5737-5744. DOI: 10.2147/CMAR.S197634.
    [30]
    LUO Q, WANG J, ZHAO W, et al. Vasculogenic mimicry in carcinogenesis and clinical applications[J]. J Hematol Oncol, 2020, 13(1): 19. DOI: 10.1186/s13045-020-00858-6.
    [31]
    ARVANITAKIS K, KOLETSA T, MITROULIS I, et al. Tumor-associated macrophages in hepatocellular carcinoma pathogenesis, prognosis and therapy[J]. Cancers (Basel), 2022, 14(1): 226. DOI: 10.3390/cancers14010226.
    [32]
    ZHAO X, SUN B, LIU T, et al. Long noncoding RNA n339260 promotes vasculogenic mimicry and cancer stem cell development in hepatocellular carcinoma[J]. Cancer Sci, 2018, 109(10): 3197-3208. DOI: 10.1111/cas.13740.
    [33]
    DONGRE A, WEINBERG RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer[J]. Nat Rev Mol Cell Biol, 2019, 20(2): 69-84. DOI: 10.1038/s41580-018-0080-4.
    [34]
    YU LX, LING Y, WANG HY. Role of nonresolving inflammation in hepatocellular carcinoma development and progression[J]. NPJ Precis Oncol, 2018, 2(1): 6. DOI: 10.1038/s41698-018-0048-z.
    [35]
    SETLAI BP, HULL R, BIDA M, et al. Immunosuppressive signaling pathways as targeted cancer therapies[J]. Biomedicines, 2022, 10(3): 682. DOI: 10.3390/biomedicines10030682.
    [36]
    WEI R, ZHU WW, YU GY, et al. S100 calcium-binding protein A9 from tumor-associated macrophage enhances cancer stem cell-like properties of hepatocellular carcinoma[J]. Int J Cancer, 2021, 148(5): 1233-1244. DOI: 10.1002/ijc.33371.
    [37]
    MANIOTIS AJ, FOLBERG R, HESS A, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry[J]. Am J Pathol, 1999, 155(3): 739-752. DOI: 10.1016/S0002-9440(10)65173-5.
    [38]
    HANAHAN D, COUSSENS LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment[J]. Cancer Cell, 2012, 21(3): 309-322. DOI: 10.1016/j.ccr.2012.02.022.
    [39]
    BALKWILL FR, CAPASSO M, HAGEMANN T. The tumor microenvironment at a glance[J]. J Cell Sci, 2012, 125(Pt 23): 5591-5596. DOI: 10.1242/jcs.116392.
    [40]
    EGGERT T, GRETEN TF. Tumor regulation of the tissue environment in the liver[J]. Pharmacol Ther, 2017, 173: 47-57. DOI: 10.1016/j.pharmthera.2017.02.005.
    [41]
    CHEN A, XU C, LUO Y, et al. Disruption of crosstalk between LX-2 and liver cancer stem-like cells from MHCC97H cells by DFOG via inhibiting FOXM1[J]. Acta Biochim Biophys Sin (Shanghai), 2019, 51(12): 1267-1275. DOI: 10.1093/abbs/gmz129.
    [42]
    TAN Z, SUN H, XUE T, et al. Liver fibrosis: therapeutic targets and advances in drug therapy[J]. Front Cell Dev Biol, 2021, 9: 730176. DOI: 10.3389/fcell.2021.730176.
    [43]
    WANG N, WANG S, LI MY, et al. Cancer stem cells in hepatocellular carcinoma: an overview and promising therapeutic strategies[J]. Ther Adv Med Oncol, 2018, 10: 1758835918816287. DOI: 10.1177/1758835918816287.
    [44]
    ZHOU W, YANG J, SAREN G, et al. HDAC6-specific inhibitor suppresses Th17 cell function via the HIF-1α pathway in acute lung allograft rejection in mice[J]. Theranostics, 2020, 10(15): 6790-6805. DOI: 10.7150/thno.44961.
    [45]
    LLOVET JM, KELLEY RK, VILLANUEVA A, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7(1): 6. DOI: 10.1038/s41572-020-00240-3.
    [46]
    SALAH MM, ASHOUR AA, ABDELGHANY TM, et al. Pirfenidone alleviates concanavalin A-induced liver fibrosis in mice[J]. Life Sci, 2019, 239: 116982. DOI: 10.1016/j.lfs.2019.116982.
    [47]
    PENG Y, LI L, ZHANG X, et al. Fluorofenidone affects hepatic stellate cell activation in hepatic fibrosis by targeting the TGF-β1/Smad and MAPK signaling pathways[J]. Exp Ther Med, 2019, 18(1): 41-48. DOI: 10.3892/etm.2019.7548.
    [48]
    STRAIGN DM, IHLE CL, PROVERA MD, et al. Targeting the BMP pathway in prostate cancer induced bone disease[J]. Front Endocrinol (Lausanne), 2021, 12: 769316. DOI: 10.3389/fendo.2021.769316.
    [49]
    KUMARI S, ADVANI D, SHARMA S, et al. Combinatorial therapy in tumor microenvironment: Where do we stand?[J]. Biochim Biophys Acta Rev Cancer, 2021, 1876(2): 188585. DOI: 10.1016/j.bbcan.2021.188585.
    [50]
    CHENG Q, LI C, YANG CF, et al. Methyl ferulic acid attenuates liver fibrosis and hepatic stellate cell activation through the TGF-β1/Smad and NOX4/ROS pathways[J]. Chem Biol Interact, 2019, 299: 131-139. DOI: 10.1016/j.cbi.2018.12.006.
    [51]
    FRIEDMAN SL, RATZIU V, HARRISON SA, et al. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis[J]. Hepatology, 2018, 67(5): 1754-1767. DOI: 10.1002/hep.29477.
    [52]
    RATAJCZAK MZ, RATAJCZAK J. Extracellular microvesicles/exosomes: discovery, disbelief, acceptance, and the future?[J]. Leukemia, 2020, 34(12): 3126-3135. DOI: 10.1038/s41375-020-01041-z.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(2)

    Article Metrics

    Article views (447) PDF downloads(87) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return